Combined cellular and biochemical profiling of Bruton’s tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers
Combined cancer cell panel and biochemical profiling reveals previously underappreciated cross-reactivities of nemtabrutinib indicating a potential application in MAPK-driven cancers.
Authors
- Janneke J. T. M. Melis
- Oscar P. J. van Linden (ORCID: https://orcid.org/0000-0002-5272-5818)
- Yvonne Grobben (ORCID: https://orcid.org/0000-0002-3460-3593)
- Guido J.R. Zaman (ORCID: https://orcid.org/0000-0002-2477-8314)
- Jeffrey J. Kooijman (ORCID: https://orcid.org/0000-0002-0533-3491)
- Esmee van den Bossche
- Daphne J. F. Kluitmans
- Jacob Ytsma
- Jeroen A.D.M. de Roos
Institutions
- Oncolie (FR)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fonc.2025.1667291
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vrije Universiteit Amsterdam